These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33883278)

  • 21. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 22. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
    Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
    Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells.
    Li X; Zhu F; Jiang J; Sun C; Zhong Q; Shen M; Wang X; Tian R; Shi C; Xu M; Peng F; Guo X; Hu J; Ye D; Wang M; Qin R
    Autophagy; 2016 Sep; 12(9):1521-37. PubMed ID: 27308733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
    Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
    BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.
    Auner HW; Moody AM; Ward TH; Kraus M; Milan E; May P; Chaidos A; Driessen C; Cenci S; Dazzi F; Rahemtulla A; Apperley JF; Karadimitris A; Dillon N
    PLoS One; 2013; 8(9):e74415. PubMed ID: 24069311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
    Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
    Parzych K; Chinn TM; Chen Z; Loaiza S; Porsch F; Valbuena GN; Kleijnen MF; Karadimitris A; Gentleman E; Keun HC; Auner HW
    Cell Death Dis; 2015 Dec; 6(12):e2031. PubMed ID: 26720340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Essential Amino Acid Availability Influences Proteostasis and Breast Cancer Cell Survival During Proteotoxic Stress.
    Sannino S; Manuel AM; Shang C; Wendell SG; Wipf P; Brodsky JL
    Mol Cancer Res; 2023 Jul; 21(7):675-690. PubMed ID: 36961392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.
    Auner HW; Cenci S
    Br J Haematol; 2015 Jan; 168(1):14-25. PubMed ID: 25296649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome Based Molecular Strategies Against Improper Cellular Proliferation.
    Dubey AR; Kinger S; Jagtap YA; Patwa SM; Kumar P; Singh S; Kumar A; Kumar A; Mishra A
    Cell Physiol Biochem; 2021 Oct; 55(S2):120-143. PubMed ID: 34655466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
    Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
    Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The stress-inducible transcription factor ATF4 accumulates at specific rRNA-processing nucleolar regions after proteasome inhibition.
    Galimberti V; Kinor N; Shav-Tal Y; Biggiogera M; Brüning A
    Eur J Cell Biol; 2016 Oct; 95(10):389-400. PubMed ID: 27567537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
    Hideshima T; Anderson KC
    Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
    Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.
    Tsvetkov P; Sokol E; Jin D; Brune Z; Thiru P; Ghandi M; Garraway LA; Gupta PB; Santagata S; Whitesell L; Lindquist S
    Proc Natl Acad Sci U S A; 2017 Jan; 114(2):382-387. PubMed ID: 28028240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.